Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(17%)
Results Posted
33%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
2
33%
Ph phase_4
3
50%
Ph phase_2
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 4Post-market surveillance
3(50.0%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Terminated1
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 43 (50.0%)
N/A2 (33.3%)

Trials by Status

terminated117%
completed350%
unknown117%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_2

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

NCT07215312
completednot_applicable

Degludec Glargine U300 Hospital Study

NCT05036876
completedphase_4

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

NCT03336528
terminatednot_applicable

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

NCT03001323
unknownphase_4

Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.

NCT04664764
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07215312Phase 2

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

Recruiting
NCT05036876Not Applicable

Degludec Glargine U300 Hospital Study

Completed
NCT03336528Phase 4

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Completed
NCT03001323Not Applicable

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

Terminated
NCT04664764Phase 4

Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.

Unknown
NCT04692415Phase 4

Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6